Drug Profile
Abacavir/lamivudine - GSK/Viatris /ViiV Healthcare
Alternative Names: Epivir/ziagen; EPZICOM; Kivexa; lamivudine/abacavir; Ziagen/EpivirLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; ViiV Healthcare
- Developer GSK; Viatris Inc; ViiV Healthcare
- Class Antiretrovirals; Cyclopentanes; Cyclopropanes; Dideoxynucleosides; Pyrimidine nucleosides; Small molecules
- Mechanism of Action HIV replication inhibitors; Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV infections
Most Recent Events
- 30 Jan 2019 Chemical structure information added
- 16 Jan 2018 Abacavir/lamivudine is still tentatively approved for HIV infections (In children, In infants, In neonates) in USA (PO) (US FDA website (PEPFAR), January 2018)
- 05 Aug 2011 ViiV healthcare files lawsuit against Teva Pharmaceutical for infringing patent US 6 417 191